CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 190 enrolled
Drug / intervention
Fish oil +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00552084
NCT00552084Phase 4Completed
CompareCT.gov

Fish Oil for Atrial Fibrillation - Effect and Mechanisms

Vanderbilt University·interventional·Posted Nov 1, 2007·Updated Dec 3, 2014

In Brief

A Phase 4 clinical trial evaluating Fish oil and Placebo for Atrial Fibrillation. Completed, enrolled 190 participants across 1 site.

Detailed Summary

Atrial fibrillation (AF) is a heart rhythm disorder that usually involves a rapid heart rate. People who take fish oil supplements may reduce the risk of a recurrence of AF. This study will evaluate the effectiveness of fish oil at decreasing the recurrence of AF and will examine the reasons why fish oil may reduce this risk.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI), eCardio Diagnostics, GlaxoSmithKline

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 1, 2007
Enrollment StartNov 1, 2007
Primary CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 6.4 yearsPosted 18.7 years ago

Interventions

Fish oildrug

Fish oil supplements 4 gms will be taken daily for 24 weeks.

Placebodrug

Placebo supplements will be taken daily for 24 weeks.